Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy.

Navid F, Santana VM, Neel M, McCarville MB, Shulkin BL, Wu J, Billups CA, Mao S, Daryani VM, Stewart CF, Kunkel M, Smith W, Ward D, Pappo AS, Bahrami A, Loeb DM, Reikes Willert J, Rao BN, Daw NC.

Int J Cancer. 2017 Oct 1;141(7):1469-1477. doi: 10.1002/ijc.30841. Epub 2017 Jul 3.

PMID:
28631382
2.

18F-FDG Uptake During Early Adjuvant Chemotherapy Predicts Histologic Response in Pediatric and Young Adult Patients with Osteosarcoma.

Davis JC, Daw NC, Navid F, Billups CA, Wu J, Bahrami A, Jenkins JJ, Snyder SE, Reddick WE, Santana VM, McCarville MB, Guo J, Shulkin BL.

J Nucl Med. 2018 Jan;59(1):25-30. doi: 10.2967/jnumed.117.190595. Epub 2017 Jun 13.

PMID:
28611244
3.

Bioluminescence Imaging Enhances Analysis of Drug Responses in a Patient-Derived Xenograft Model of Pediatric ALL.

Jones L, Richmond J, Evans K, Carol H, Jing D, Kurmasheva RT, Billups CA, Houghton PJ, Smith MA, Lock RB.

Clin Cancer Res. 2017 Jul 15;23(14):3744-3755. doi: 10.1158/1078-0432.CCR-16-2392. Epub 2017 Jan 24.

PMID:
28119366
4.

Ocular Salvage and Vision Preservation Using a Topotecan-Based Regimen for Advanced Intraocular Retinoblastoma.

Brennan RC, Qaddoumi I, Mao S, Wu J, Billups CA, Stewart CF, Hoehn ME, Rodriguez-Galindo C, Wilson MW.

J Clin Oncol. 2017 Jan;35(1):72-77. Epub 2016 Oct 31.

5.

Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis.

Murphy B, Yin H, Maris JM, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Keir ST, Kurmasheva RT, Dvorchik I, Wu J, Billups CA, Boateng N, Smith MA, Lock RB, Houghton PJ.

Cancer Res. 2016 Oct 1;76(19):5798-5809. Epub 2016 Aug 5.

6.

Patients with retinoblastoma and chromosome 13q deletions have increased chemotherapy-related toxicities.

Brennan RC, Qaddoumi I, Billups CA, Kaluzny T, Furman WL, Wilson MW.

Pediatr Blood Cancer. 2016 Nov;63(11):1954-8. doi: 10.1002/pbc.26138. Epub 2016 Jul 13.

7.

Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia.

Khaw SL, Suryani S, Evans K, Richmond J, Robbins A, Kurmasheva RT, Billups CA, Erickson SW, Guo Y, Houghton PJ, Smith MA, Carol H, Roberts AW, Huang DC, Lock RB.

Blood. 2016 Sep 8;128(10):1382-95. doi: 10.1182/blood-2016-03-707414. Epub 2016 Jun 24.

8.

Cognitive outcomes among survivors of focal low-grade brainstem tumors diagnosed in childhood.

Clark KN, Ashford JM, Pai Panandiker AS, Klimo P, Merchant TE, Billups CA, Conklin HM.

J Neurooncol. 2016 Sep;129(2):311-7. doi: 10.1007/s11060-016-2176-z. Epub 2016 Jun 16.

9.

Acute Sensitivity of Ph-like Acute Lymphoblastic Leukemia to the SMAC-Mimetic Birinapant.

Richmond J, Robbins A, Evans K, Beck D, Kurmasheva RT, Billups CA, Carol H, Heatley S, Sutton R, Marshall GM, White D, Pimanda J, Houghton PJ, Smith MA, Lock RB.

Cancer Res. 2016 Aug 1;76(15):4579-91. doi: 10.1158/0008-5472.CAN-16-0523. Epub 2016 Jun 14.

10.

Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021.

Wetmore C, Daryani VM, Billups CA, Boyett JM, Leary S, Tanos R, Goldsmith KC, Stewart CF, Blaney SM, Gajjar A.

Cancer Med. 2016 Jul;5(7):1416-24. doi: 10.1002/cam4.713. Epub 2016 Apr 25.

11.

Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program.

Gorlick R, Kolb EA, Keir ST, Maris JM, Lock RB, Carol H, Reynolds CP, Kang MH, Billups CA, Collins J, Kurmashev D, Kurmasheva RT, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2016 Mar;63(3):443-50. doi: 10.1002/pbc.25826. Epub 2015 Nov 24.

12.

Pulmonary Function After Treatment for Embryonal Brain Tumors on SJMB03 That Included Craniospinal Irradiation.

Green DM, Merchant TE, Billups CA, Stokes DC, Broniscer A, Bartels U, Chintagumpala M, Hassall TE, Gururangan S, McCowage GB, Heath JA, Cohn RJ, Fisher MJ, Srinivasan A, Robinson GW, Gajjar A.

Int J Radiat Oncol Biol Phys. 2015 Sep 1;93(1):47-53. doi: 10.1016/j.ijrobp.2015.05.019. Epub 2015 May 19.

13.

Comparison of high-risk histopathological features in eyes with primary or secondary enucleation for retinoblastoma.

Brennan RC, Qaddoumi I, Billups CA, Free TL, Haik BG, Rodriguez-Galindo C, Wilson MW.

Br J Ophthalmol. 2015 Oct;99(10):1366-71. doi: 10.1136/bjophthalmol-2014-306364. Epub 2015 Apr 14.

14.

Ocular abnormalities in patients treated with a novel anti-GD2 monoclonal antibody, hu14.18K322A.

Tse BC, Navid F, Billups CA, O'Donnell T, Hoehn ME.

J AAPOS. 2015 Apr;19(2):112-5. doi: 10.1016/j.jaapos.2014.11.005. Epub 2015 Mar 26.

15.

Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia.

Suryani S, Bracken LS, Harvey RC, Sia KC, Carol H, Chen IM, Evans K, Dietrich PA, Roberts KG, Kurmasheva RT, Billups CA, Mullighan CG, Willman CL, Loh ML, Hunger SP, Houghton PJ, Smith MA, Lock RB.

Mol Cancer Ther. 2015 Feb;14(2):364-74. doi: 10.1158/1535-7163.MCT-14-0647. Epub 2014 Dec 10.

16.

Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program.

Smith MA, Reynolds CP, Kang MH, Kolb EA, Gorlick R, Carol H, Lock RB, Keir ST, Maris JM, Billups CA, Lyalin D, Kurmasheva RT, Houghton PJ.

Clin Cancer Res. 2015 Feb 15;21(4):819-32. doi: 10.1158/1078-0432.CCR-14-2572. Epub 2014 Dec 10. Erratum in: Clin Cancer Res. 2017 Feb 15;23 (4):1118-1119.

17.

A comparison of function after limb salvage with non-invasive expandable or modular prostheses in children.

Ness KK, Neel MD, Kaste SC, Billups CA, Marchese VG, Rao BN, Daw NC.

Eur J Cancer. 2014 Dec;50(18):3212-20.

18.

Recurrent osteosarcoma with a single pulmonary metastasis: a multi-institutional review.

Daw NC, Chou AJ, Jaffe N, Rao BN, Billups CA, Rodriguez-Galindo C, Meyers PA, Huh WW.

Br J Cancer. 2015 Jan 20;112(2):278-82. doi: 10.1038/bjc.2014.585. Epub 2014 Nov 25.

19.

Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program.

Kolb EA, Gorlick R, Billups CA, Hawthorne T, Kurmasheva RT, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2014 Oct;61(10):1816-21. doi: 10.1002/pbc.25099. Epub 2014 Jun 9.

20.

Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma.

Navid F, Sondel PM, Barfield R, Shulkin BL, Kaufman RA, Allay JA, Gan J, Hutson P, Seo S, Kim K, Goldberg J, Hank JA, Billups CA, Wu J, Furman WL, McGregor LM, Otto M, Gillies SD, Handgretinger R, Santana VM.

J Clin Oncol. 2014 May 10;32(14):1445-52. doi: 10.1200/JCO.2013.50.4423. Epub 2014 Apr 7.

21.

Subsequent malignant neoplasms in pediatric patients initially diagnosed with neuroblastoma.

Federico SM, Allewelt HB, Spunt SL, Hudson MM, Wu J, Billups CA, Jenkins J, Santana VM, Furman WL, McGregor LM.

J Pediatr Hematol Oncol. 2015 Jan;37(1):e6-e12. doi: 10.1097/MPH.0000000000000148.

22.

Pathologic risk-based adjuvant chemotherapy for unilateral retinoblastoma following enucleation.

Sullivan EM, Wilson MW, Billups CA, Wu J, Merchant TE, Brennan RC, Haik BG, Shulkin B, Free TM, Given V, Rodriguez-Galindo C, Qaddoumi I.

J Pediatr Hematol Oncol. 2014 Aug;36(6):e335-40. doi: 10.1097/MPH.0000000000000141.

23.

Clinical features and outcomes of young patients with head and neck non-rhabdomyosarcoma soft tissue sarcomas.

Federico SM, Gilpin D, Samant S, Billups CA, Spunt SL.

Head Neck. 2015 Jan;37(1):76-83. doi: 10.1002/hed.23564. Epub 2014 Feb 12.

PMID:
24327514
24.

Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.

Gorlick R, Kolb EA, Keir ST, Maris JM, Reynolds CP, Kang MH, Carol H, Lock R, Billups CA, Kurmasheva RT, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2014 Jan;61(1):158-64. doi: 10.1002/pbc.24616. Epub 2013 Aug 19.

25.

Survival of pediatric patients after relapsed osteosarcoma: the St. Jude Children's Research Hospital experience.

Leary SE, Wozniak AW, Billups CA, Wu J, McPherson V, Neel MD, Rao BN, Daw NC.

Cancer. 2013 Jul 15;119(14):2645-53. doi: 10.1002/cncr.28111. Epub 2013 Apr 26.

26.

Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program.

Kolb EA, Gorlick R, Reynolds CP, Kang MH, Carol H, Lock R, Keir ST, Maris JM, Billups CA, Desjardins C, Kurmasheva RT, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2013 Aug;60(8):1325-32. doi: 10.1002/pbc.24517. Epub 2013 Mar 28.

27.

Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program.

Lock RB, Carol H, Maris JM, Kang MH, Reynolds CP, Kolb EA, Gorlick R, Keir ST, Billups CA, Kurmasheva RT, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2013 Jul;60(7):E42-5. doi: 10.1002/pbc.24451. Epub 2013 Jan 9.

28.

Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors.

Navid F, Baker SD, McCarville MB, Stewart CF, Billups CA, Wu J, Davidoff AM, Spunt SL, Furman WL, McGregor LM, Hu S, Panetta JC, Turner D, Fofana D, Reddick WE, Leung W, Santana VM.

Clin Cancer Res. 2013 Jan 1;19(1):236-46. doi: 10.1158/1078-0432.CCR-12-1897. Epub 2012 Nov 8. Erratum in: Clin Cancer Res. 2013 Apr 1;19(7):1914.

29.

Intensity modulated radiation therapy provides excellent local control in high-risk abdominal neuroblastoma.

Pai Panandiker AS, Beltran C, Billups CA, McGregor LM, Furman WL, Davidoff AM.

Pediatr Blood Cancer. 2013 May;60(5):761-5. doi: 10.1002/pbc.24350. Epub 2012 Sep 28.

PMID:
23024112
30.

Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program.

Reynolds CP, Kang MH, Carol H, Lock R, Gorlick R, Kolb EA, Kurmasheva RT, Keir ST, Maris JM, Billups CA, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2013 May;60(5):791-8. doi: 10.1002/pbc.24301. Epub 2012 Sep 21.

31.

Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program.

Carol H, Reynolds CP, Kang MH, Keir ST, Maris JM, Gorlick R, Kolb EA, Billups CA, Geier B, Kurmasheva RT, Houghton PJ, Smith MA, Lock RB.

Pediatr Blood Cancer. 2013 Apr;60(4):633-41. doi: 10.1002/pbc.24235. Epub 2012 Jul 2.

32.

Timing of surgery and the role of adjuvant radiotherapy in ewing sarcoma of the chest wall: a single-institution experience.

Denbo JW, Shannon Orr W, Wu Y, Wu J, Billups CA, Navid F, Rao BN, Davidoff AM, Krasin MJ.

Ann Surg Oncol. 2012 Nov;19(12):3809-15. doi: 10.1245/s10434-012-2449-5. Epub 2012 Jul 3.

33.

Analysis of prognostic factors in extraosseous Ewing sarcoma family of tumors: review of St. Jude Children's Research Hospital experience.

Orr WS, Denbo JW, Billups CA, Wu J, Navid F, Rao BN, Davidoff AM, Krasin MJ.

Ann Surg Oncol. 2012 Nov;19(12):3816-22. doi: 10.1245/s10434-012-2458-4. Epub 2012 Jun 28. Erratum in: Ann Surg Oncol. 2013 Dec;20 Suppl 3:S753. Shannon Orr, W [corrected to Orr, W Shannon].

PMID:
22739653
34.

Is routine pelvic surveillance imaging necessary in patients with Wilms tumor?

Kaste SC, Brady SL, Yee B, McPherson VJ, Kaufman RA, Billups CA, Daw NC, Pappo AS.

Cancer. 2013 Jan 1;119(1):182-8. doi: 10.1002/cncr.27687. Epub 2012 Jun 26.

35.

Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma.

Metzger ML, Weinstein HJ, Hudson MM, Billett AL, Larsen EC, Friedmann A, Howard SC, Donaldson SS, Krasin MJ, Kun LE, Marcus KJ, Yock TI, Tarbell N, Billups CA, Wu J, Link MP.

JAMA. 2012 Jun 27;307(24):2609-16. doi: 10.1001/jama.2012.5847.

36.

Topotecan and vincristine combination is effective against advanced bilateral intraocular retinoblastoma and has manageable toxicity.

Qaddoumi I, Billups CA, Tagen M, Stewart CF, Wu J, Helton K, McCarville MB, Merchant TE, Brennan R, Free TM, Given V, Haik BG, Rodriguez-Galindo C, Wilson MW.

Cancer. 2012 Nov 15;118(22):5663-70. doi: 10.1002/cncr.27563. Epub 2012 Apr 19.

37.

Association of age at diagnosis and genetic mutations in patients with neuroblastoma.

Cheung NK, Zhang J, Lu C, Parker M, Bahrami A, Tickoo SK, Heguy A, Pappo AS, Federico S, Dalton J, Cheung IY, Ding L, Fulton R, Wang J, Chen X, Becksfort J, Wu J, Billups CA, Ellison D, Mardis ER, Wilson RK, Downing JR, Dyer MA; St Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project.

JAMA. 2012 Mar 14;307(10):1062-71. doi: 10.1001/jama.2012.228.

38.

Carboplatin-associated ototoxicity in children with retinoblastoma.

Qaddoumi I, Bass JK, Wu J, Billups CA, Wozniak AW, Merchant TE, Haik BG, Wilson MW, Rodriguez-Galindo C.

J Clin Oncol. 2012 Apr 1;30(10):1034-41. doi: 10.1200/JCO.2011.36.9744. Epub 2012 Feb 27.

39.

Evaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma.

Smith MA, Kang MH, Reynolds CP, Kurmasheva RT, Alexander D, Billups CA, Toretsky JA, Houghton PJ.

Pediatr Blood Cancer. 2012 Oct;59(4):753-5. doi: 10.1002/pbc.23391. Epub 2012 Feb 7.

40.

Dynamic contrast-enhanced magnetic resonance imaging as a prognostic factor in predicting event-free and overall survival in pediatric patients with osteosarcoma.

Guo J, Reddick WE, Glass JO, Ji Q, Billups CA, Wu J, Hoffer FA, Kaste SC, Jenkins JJ, Ortega Flores XC, Quintana J, Villarroel M, Daw NC.

Cancer. 2012 Aug 1;118(15):3776-85. doi: 10.1002/cncr.26701. Epub 2011 Dec 16.

41.

Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program.

Gorlick R, Maris JM, Houghton PJ, Lock R, Carol H, Kurmasheva RT, Kolb EA, Keir ST, Reynolds CP, Kang MH, Billups CA, Smith MA.

Pediatr Blood Cancer. 2012 Sep;59(3):518-24. doi: 10.1002/pbc.23412. Epub 2011 Nov 18.

42.

Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program.

Batra V, Maris JM, Kang MH, Reynolds CP, Houghton PJ, Alexander D, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Billups CA, Smith MA.

Pediatr Blood Cancer. 2012 Oct;59(4):749-52. doi: 10.1002/pbc.23364. Epub 2011 Nov 2.

43.

A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma.

Furman WL, McGregor LM, McCarville MB, Onciu M, Davidoff AM, Kovach S, Hawkins D, McPherson V, Houghton PJ, Billups CA, Wu J, Stewart CF, Santana VM.

Invest New Drugs. 2012 Aug;30(4):1660-70. doi: 10.1007/s10637-011-9724-3. Epub 2011 Jul 28.

44.

Phantom limb pain in young cancer-related amputees: recent experience at St Jude children's research hospital.

Burgoyne LL, Billups CA, Jirón JL Jr, Kaddoum RN, Wright BB, Bikhazi GB, Parish ME, Pereiras LA.

Clin J Pain. 2012 Mar-Apr;28(3):222-5. doi: 10.1097/AJP.0b013e318227ce7a.

45.

Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program.

Houghton PJ, Kang MH, Reynolds CP, Morton CL, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Maris JM, Billups CA, Smith MA.

Pediatr Blood Cancer. 2012 Apr;58(4):636-9. doi: 10.1002/pbc.23167. Epub 2011 Jun 16.

46.

Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children's Research Hospital OS99 trial.

Daw NC, Neel MD, Rao BN, Billups CA, Wu J, Jenkins JJ, Quintana J, Luchtman-Jones L, Villarroel M, Santana VM.

Cancer. 2011 Jun 15;117(12):2770-8. doi: 10.1002/cncr.25715. Epub 2011 Jan 10.

47.

Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program.

Houghton PJ, Lock R, Carol H, Morton CL, Gorlick R, Anders Kolb E, Keir ST, Reynolds CP, Kang MH, Maris JM, Billups CA, Zhang MX, Madden SL, Teicher BA, Smith MA.

Pediatr Blood Cancer. 2012 Feb;58(2):200-9. doi: 10.1002/pbc.23016. Epub 2011 May 5.

48.

Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program.

Morton CL, Maris JM, Keir ST, Gorlick R, Kolb EA, Billups CA, Wu J, Smith MA, Houghton PJ.

Pediatr Blood Cancer. 2012 Apr;58(4):566-71. doi: 10.1002/pbc.23159. Epub 2011 Apr 29.

49.

Initial testing of lenalidomide by the pediatric preclinical testing program.

Reynolds CP, Kang MH, Keir ST, Gorlick R, Kolb EA, Lock R, Maris JM, Carol H, Morton CL, Billups CA, Smith MA, Houghton PJ.

Pediatr Blood Cancer. 2011 Oct;57(4):606-11. doi: 10.1002/pbc.22877. Epub 2011 Feb 25.

50.

Evaluation of cytarabine against Ewing sarcoma xenografts by the pediatric preclinical testing program.

Houghton PJ, Morton CL, Kang M, Reynolds CP, Billups CA, Favours E, Payne-Turner D, Tucker C, Smith MA.

Pediatr Blood Cancer. 2010 Dec 1;55(6):1224-6. doi: 10.1002/pbc.22355.

Supplemental Content

Loading ...
Support Center